Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer

  • Authors:
    • Jianjie Zhu
    • Yuanyuan Zeng
    • Chun Xu
    • Hualong Qin
    • Zhe Lei
    • Dan Shen
    • Zeyi Liu
    • Jian-An Huang
  • View Affiliations

  • Published online on: July 21, 2015     https://doi.org/10.3892/or.2015.4141
  • Pages: 1779-1786
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide and although there have been improvements in treatment there is a low survival rate. The aim of the present study was to investigate the effect of microRNA (miRNA) on cell pathways. A miRNA microarray was used to profile miRNAs of lung cancer tissues. It was identified that 33 miRNAs with >2.0-fold change and FDR <0.05 were differentially expressed between the adjacent non-cancerous lung tissues and non-small cell lung cancers NSCLCs (P<0.005). The data were optimized in combination with physical interaction analysis to obtain crucial miRNAs. The results showed that differentially expressed miRNAs were associated with biological processes such as cell migration, protein phosphorylation and neuron differentiation, and signaling pathways such as MAPK, TGF-β and PI3K/Akt signaling pathways. Validation of significant miRNAs in independent 40 paired NSCLC tissues demonstrated that the expression level of miR-486-5p and miR-30a-5p was significantly downregulated in another 40 paired lung cancer tissues. Taken together, the results provided strong evidence of the possible involvement of miRNAs in the development and progression of NSCLC. Thus, the results are of importance for clinical investigators and for those who design miRNA‑based novel cancer therapeutics.

Introduction

Lung cancer is the leading cause of cancer-related mortality worldwide (1), with non-small cell lung cancer (NSCLC) accounting for 80% of all cases of lung cancer. Despite improvement in cancer treatment, the 5-year survival rate remains at <10%. However, diagnosis followed by treatment in the form of surgery at early stage may lead to a 5-year survival rate of 55–80% (2). Therefore, preferential understanding of the mechanisms of tumor development and progression are of great importance in early detection and prevention as well as the targeted treatment of NSCLC.

MicroRNA (miRNA) are a class of small non-coding RNAs between 19 and 24 nt that can repress translation or promote the degradation of target mRNAs (3,4). It has been confirmed that approximately 30% of human protein-coding genes are regulated by miRNAs (5). Thus, miRNAs play an important role in regulating various biological processes, such as cell proliferation (6), differentiation (7) and apoptosis (8). Previous findings showed that an altered expression of miRNAs in cancer relative to corresponding normal tissues, and specific expression signatures or panels can classify human cancers (9), distinguish tumor subtype (10), and are closely associated with prognosis (11). In a recent study, it was shown that altered miRNAs can regulate epithelial-to-mesenchymal transition (EMT) in tumor progression (12). Moreover, increasing evidence suggested that dysregulation of miRNAs contributed to stem cell fate (13).

hsa-miR-486-5p is located on chromosome 8p11.21, which is one of the most frequent genomic deletion regions that contain potential tumor-suppressor genes in various types of tumors, such as NSCLC (14,15). hsa-miR-486-5p was first cloned from the fetal liver. Additionally, a reduced miR-486-5p expression is a frequent molecular event in human malignances (1619).

hsa-miR-30a-5p is a member of the microRNA-30 family, and is located on chromosome 6q13, which has been reported to be a genomic fragile region due to loss of heterozygosity in breast and lung cancer (20,21). miR-30a-5p has received more attention due to its important role in various biological and pathological processes, including development, differentiation, autophage and apoptosis (22,23).

In the present study, the microRNA microarray was employted to profile miRNA of lung cancer tissues from Chinese subjects. The data were optimized in combination with physical interaction analysis to obtain crucial miRNAs. The results showed the expression level of miR-486-5p and miR-30a-5p was significantly downregulated in another 40 paired lung cancer tissues.

Materials and methods

Patients and tissue samples

Forty-four paired NSCLC and adjacent non-cancerous lung tissues were collected at the time of surgery and before chemotherapy. The samples were obtained from patients at the First Affiliated Hospital of the Soochow University between 2007 and 2013. Informed consent was provided the patients participating in the study. Histological and pathological diagnostics of tissue samples from the patients were obtained from the Department of Pathology according to the Revised International System for Staging Lung Cancer. Tissue samples were snap-frozen and stored in an cryofreezer at −80°C. Study approval was obtained by the Ethics Committee of the First Affiliated Hospital of Soochow University.

Analysis of miRNA microarray

miRNA microarray assays were performed using the Agilent Human miRNA microarray platform (Agilent Technologies, Santa Clara, CA, USA) at Shanghai Biochip Co., Ltd. (Shanghai, China). The microarray containing probes for 2006 human miRNAs from the Sanger database V19.0. Total RNA (100 ng) derived from cells was labeled with Cy3. Microarray slides were scanned using an Agilent microarray scanner. Labeling and hybridization were performed according to the instructions in the Agilent microRNAs microarray system. The microarray image information was converted into spot intensity values using Feature Extraction software 10.7 (Agilent Technologies). The signal after background subtraction was exported directly into the GeneSpring software 11.0 (Agilent Technologies) for quantile normalization. Log transformation with base 2 was then performed. The limma algorithm (24) was then applied to filter the differentially expressed genes, after the significant analysis and FDR analysis (25) under the specified criteria: i), fold change >2 or <0.5; and ii), FDR <0.05. Targetscan 6.1 was utilized as the tool for predicting miRNA target on the differentially expressed miRNA.

Gene ontology (GO) analysis

GO analysis was performed to facilitate elucidating the biological implications of unique genes in the significant or representative profiles of the target gene of the differentially expressed miRNA in the experiment (26). The GO annotations were downloaded from NCBI (http://www.ncbi.nlm.nih.gov/), UniProt (http://www.uniprot.org/) and the Gene Ontology (http://www.geneontology.org/). Fisher's exact test was applied to identify the significant GO categories and FDR was used to correct the p-values.

GO-Tree

The Gene Ontology is structured as a directed acyclic graph, and each term has defined relationships to one or more other terms. GO-Tree is constructed based on the Gene Ontology Directed Acyclic Graph to provide user friendly data navigation and visualization. The significant GO-Term (P<0.01) in GO analysis was selected based on the up and down differentially expressed genes to construct the GO-Tree to summarize the function affected in the experiment (27).

Pathway analysis

Pathway analysis was used to identify the significant pathway of the differential genes according to the KEGG database. The Fisher's exact test was used to select the significant pathway, and the threshold of significance was defined by p-value and FDR (28).

Path-act-network

KEGG included metabolism, membrane transport, signal transduction and cell cycle pathways. Genes in the enriched biological pathway were selected (P<0.05) and Cytoscape (29) was used for the graphical representations of pathways.

RNA isolation, cDNA synthesis, and reverse transcriptase-quantitative polymerase chain reaction (qRT-PCR)

Total RNA was extracted from tissues using an HP Total RNA kit (omega Biotech, Stamford, CT, USA) according to the manufacturer's instructions. The amount of RNA was measured on a NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA). Synthesis of cDNA with reverse transcriptase (RT) was performed with a M-MLV First Strand kit (Life Technologies, gaithersburg, MD, USA). Primer sequences for miR-486-5p, miR-30a-5p and u6 detection were obtained from Riobobio (Guangzhou, China). The RT primer for mature miRNAs and u6 was designed according to the concept of a stem-loop RT primer (30). RT-qPCR analysis was carried out using Platinum SYBR-green qPCR SuperMix-UDG kits (life Technologies) according to the manufacturer's instructions. Real-time PCR was performed on an ABI Prism 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Ct values of miRNAs were equilibrated to u6, which were used as internal controls. Relative expression was calculated using the ΔΔCt method.

Statistical analysis

Differences in miR-486-5p and miR-30a-5p expression between NSCLC (T) and adjacent paired noncancerous lung tissues (N) were analyzed using a paired t-test (two-tailed) by GraphPad Prism 5.0 (GraphPad, San Diego, CA, USA). The Fisher's exact was applied to identify the significant GO categories and FDR was used to correct the p-values. The Chi-square test was used with SPSS16.0 software to test independence between two variables (SPSS, Chicago, IL, USA).

Results

Differentially expressed miRNAs in NSCLC

We applied the limma algorithm to filter the differentially expressed genes, followed by the significant analysis and FDR analysis under the specified criteria: i), fold change >2 or <0.5; and ii), FDR <0.05. The data from miRNA expression profiling indicated that 33 miRNAs with >2.0-fold change and FDR <0.05 were differentially expressed between the lung normal tissue and NSCLCs (P<0.005), with a higher expression in NSCLC for 15 miRNAs and a lower expression for 18 miRNAs (Fig. 1). Among the miRNAs with a decreased expression, miR-486-5p and miR-30a-5p were identified as the most significantly downregulated, respectively, by bioinformatics.

Physical interaction analysis

Based on the miRNA array data, to identify the effect of the differentially expressed miRNA towards the biological process and signal transduction on the lung cancer, GO analysis was performed to facilitate elucidating the biological implications of unique genes in the significant or representative profiles of the target gene of the the differentially expressed miRNA in the experiment (Fig. 2), The Gene Ontology is structured as a directed acyclic graph, and each term has defined relationships to one or more other terms. The GO-Tree is constructed based on the Gene Ontology Directed Acyclic Graph to provide user friendly data navigation and visualization. The significant GO-Term (P<0.01) in GO analysis was selected based on the up and down differentially expressed genes to construct the GO-Tree to summarize the function affected in the experiment (Fig. 3).

It has been widely accepted that in solid tumors miRNAs are deregulated, suggesting their involvement in crucial cell pathways including cell-cell adhesion and signaling, cell cycle regulation and apoptosis, which play a significant role in the pathogenesis of cancer. Enriched KEGG and pathway act networks for several miRNAs target sets were frequently associated with cell signaling pathways, such as the MAPK, Wnt and PI3K-AKT signaling pathways, but also with cell migration, cytoskeleton. Thus, the significant pathway of the differential genes according to the KEGG database was idntified (Fig. 4), and the genes in the enriched biological pathway were selected (P<0.05). Cytoscape was used for the graphical representations of pathways (Fig. 5).

Validation of miRNA microarray results by RT-qPCR in NSCLC

To validate the results of miRNA microarray, miR-486-5p and miR-30a-5p were selected and assessed on the paired tissues of 40 NSCLC patients using RT-qPCR. The RT-qPCR results indicated that miR-486-5p and miR-30a-5p were significantly downregulated in NSCLCs samples used for validation, which was consistent with the results of miRNA microarray (Fig. 6).

Expression of miR-486-5p and miR-30a-5p in relation to clinicopathological characteristics

Patient characteristics with respect to the decreased expression of miR-486-5p and miR-30a-5p are shown in Table I. miR-486-5p and miR-30a-5p exhibited no association with patient age, gender, histology, lymph node status, smoking history and distant metastases. To a certain degree, these results suggeseted that the changes in miR-486-5p or miR-30a-5p may occur at the early stage of tumorigenesis, rather than during cancer progression or metastasis.

Table I

Demographic and clinical characteristics of NSCLC patients and the association with miR-486-5p and miR-30a-5p expression in tumor tissue specimens.

Table I

Demographic and clinical characteristics of NSCLC patients and the association with miR-486-5p and miR-30a-5p expression in tumor tissue specimens.

CharacteristicsAll patients
Patients with lower miR-30a-5p expression
Patients with lower miR-486-5p expression
n%n%P-valuean%P-valuea
All patients403485.035
Age (years)
 ≥602972.52573.50.9212674.30.862
 <601127.5926.5925.7
Gender
 Male2870.02676.50.5322571.40.892
 Female1230.0823.51028.6
Histology
 Adenocarcinomas2050.01441.20.4481645.70.711
 Squamous cell carcinomas2050.02058.81954.3
Smokers
 Yes2665.02470.60.6092365.70.948
 No1435.01029.41234.3
Degree of differentiation
 Low1742.51750.00.5191748.60.598
 Middle2357.51750.01851.4
Lymph node metastasis
 No2352.51955.90.8891954.30.780
 Yes1742.51544.11645.7
Distant metastasis
 No3382.52985.30.7453085.70.705
 Yes717.5514.7514.3
Histology grade
 I/II2152.51647.10.6411748.60.734
 III/IV1947.51852.91851.4

a Chi-square test; NSCLC, non-small cell lung cancer.

Discussion

An incremental improvement in the survival rate of patients with cancer has been observed over the last several decades. However, survival advances identified in other common malignancies have not been realized in lung cancer, which remains the leading cause of cancer mortality worldwide (1). The current 5-year survival rate for lung cancer is only 15%.

Up to 25% of all lung cancer cases are not associated with smoking and this proportion is expected to increase as the number of smoking-associated cancer types decreases. The molecular genetic alterations including genetic and epigenetic ones occur prior to morphological changes that can be identified by a cytological test (3134). miRNA expression has been directly profiled in lung cancer, and unique groups of miRNAs were identified to characterize the neoplastic tissues or identify patients with poor prognosis (10,3537).

In this study, we used miRNA expression arrays to determine the miRNA profiles for NSCLC and paired adjacent non-cancerous lung tissues. The miRNA expression profiles distinguished NSCLC from normal lung tissue, and the samples were classified into two clusters: normal and NSCLC. The expression levels of miR-486-5p and miR-30a-5p were determined by RT-qPCR and consistent with the results of miRNA microarray in 80 samples.

Among miRNAs identified (P<0.005), a few of the miRNAs, including miR-21 and miR-200b were found to be upregulated in NSCLCs. These results were consistent with those of Tan et al and Yu et al (17,38). miR-21 is one of the best-studied miRNAs, and more extensive efforts have been taken to identify the downstream genes and gene networks regulated by miR-21 and the upstream factors that can regulate dysfunction of miR-21. miR-21 can serve as an important biomarker for the early detection of lung cancer (38), and a high level of miR-21 is associated with worse prognosis of lung cancer patients. miR-200b, located on chromosome 1p36.33, is one of the most common regions with genomic amplications in solid tumors including lung cancer (39). Although the biological mechanism of miR-200b dysfunction in lung tumorigenesis is unclear, miR-200b has been recently identified as one of a set of miRNAs whose aberrant expression was associated with recurrence of stage I NSCLC after surgical resection (40). Consistently, we found that miR-200b overexpression existed in microRNA expression profiles data.

By contrast, a few of the miRNAs, including miR-486-5p and miR-30a-5p were found to be significantly downregulated in NSCLCs. miR-486 is located on one of the most frequent genomic rearrangement regions, chromosome 8p11.21, which contains potential tumor-suppressor genes in lung tumorigenesis. Recent findings have shown miR-486-5p plays a critical role in breast and lung cancer by targeted PIM-1 (41,42). The results from the present study are consistent with those of previous findings, suggesting that miR-486-5p is a potential tumor suppressor in carcinogenesis. miR-30a-5p is a member of the microRNA-30 family, located on chromosome 6q13, which has been reported to be a genomic fragile region due to loss of heterozygosity in breast and lung cancer (20,21). Zhang et al showed that miR-30a-5p can suppress breast tumor growth and metastasis by targeting metadherin (43). In lung cancer, Kumarswamy et al showed that miR-30a is downregulated in NSCLC and inhibits EMT by targeting Snail (44).

It has been widely accepted the tumorigenesis is a heterogeneous disease and develops from complex and multistep processes, including lung cancer. Evidence suggests that multiple signaling pathways involve the development of lung cancer. A meta-analysis of microRNA expression in lung cancer suggested that significant miRNAs are regulatory drivers of the oncogenic process, and may be good candidates for the development of tests for monitoring remission during postoperative follow-up, this is supported by the gene enrichment analysis (45). In our study, based on the miRNA profiles in lung cancer, an enrichment analysis was carried out, and the results showed differentially expressed miRNAs associated with the biological process and signaling pathway in lung cancer.

In conclusion, based on the miRNA array combined with the physical interaction analysis, our results have shown the impact of significant miRNAs on cell pathways and biological processes. Further validation of miRNA microarray results by RT-qPCR in NSCLC show that miR-486-5p and miR-30a-5p were significantly downregulated in NSCLC tissues. Therefore, the results provide strong evidence of the possible involvement of miRNAs in the development and progression of NSCLC, The findings are of importance for both clinical investigators and for those who design miRNA-based novel cancer therapeutics.

Acknowledgments

We are grateful for the participation and cooperation from the patients with NSCLC. This study was supported by grants from the National Natural Science Foundation of China (31270940 to J.-A. Huang; 81201575 to Z.-Y. Liu), the Science and Technology Committee of Jiangsu Province (BK2012606 to J.-A. Huang), the Jiangsu Province Colleges and Universities Natural Science Research Foundation (12KJB310016 to Z.-Y. Liu), and the Foundation of Health Care Rejuvenation by Science and Education (KJXW2011006 to Z.-Y. Liu) and Clinical Key Speciality Project of China.

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Wang T, Nelson RA, Bogardus A and Grannis FW Jr: Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Wilson RC and Doudna JA: Molecular mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Bueno MJ, Pérez de Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle. 7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Lee CT, Risom T and Strauss WM: MicroRNAs in mammalian development. Birth Defects Res C Embryo Today. 78:129–139. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, et al: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 27:2030–2037. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Chao CH, Chang CC, Wu MJ, Ko HW, Wang D, Hung MC, Yang JY and Chang CJ: MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest. 124:3093–3106. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Midorikawa Y, Yamamoto S, Tsuji S, Kamimura N, Ishikawa S, Igarashi H, Makuuchi M, Kokudo N, Sugimura H and Aburatani H: Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology. 49:513–522. 2009. View Article : Google Scholar

15 

Jiang F, Yin Z, Caraway NP, Li R and Katz RL: Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia. 6:623–635. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M, et al: Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI

17 

Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, et al: Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther. 9:3396–3409. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 33:1181–1189. 2014. View Article : Google Scholar :

20 

Noviello C, Courjal F and Theillet C: Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: Possibly four regions of deletion. Clin Cancer Res. 2:1601–1606. 1996.PubMed/NCBI

21 

Hu XY, Bai XM, Qiao X and Zhu YQ: Copy number variation at 6q13 is associated with lung cancer risk in a Han Chinese population. Exp Lung Res. 39:427–433. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Agrawal R, Tran U and Wessely O: The miR-30 miRNA family regulates Xenopus pronephros development and targets the transcription factor Xlim1/lhx1. Development. 136:3927–3936. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, Liu Cg and Yang JM: Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy. 5:816–823. 2009. View Article : Google Scholar : PubMed/NCBI

24 

Wettenhall JM and Smyth GK: limmaGUI: A graphical user interface for linear modeling of microarray data. Bioinformatics. 20:3705–3706. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Benjamini Y, Drai D, Elmer G, Kafkafi N and Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 125:279–284. 2001. View Article : Google Scholar : PubMed/NCBI

26 

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al The Gene Ontology Consortium: Gene ontology: Tool for the unification of biology. Nat genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI

27 

Zhang B, Schmoyer D, Kirov S and Snoddy J: GOTree Machine (GOTM): A web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics. 5:162004. View Article : Google Scholar : PubMed/NCBI

28 

Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C and Romero R: A systems biology approach for pathway level analysis. Genome Res. 17:1537–1545. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Varkonyi-Gasic E, Wu R, Wood M, Walton EF and Hellens RP: Protocol: A highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods. 3:122007. View Article : Google Scholar : PubMed/NCBI

31 

Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, et al: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66:3338–3344. 2006. View Article : Google Scholar : PubMed/NCBI

32 

Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL and Stass SA: Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer. 66:58–63. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Liu Z, Zhao J, Chen XF, Li W, Liu R, Lei Z, Liu X, Peng X, Xu K, Chen J, et al: CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung Cancer. 62:15–22. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Liu Z, Li W, Lei Z, Zhao J, Chen XF, Liu R, Peng X, Wu ZH, Chen J, Liu H, et al: CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol. 5:790–797. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 13:48–57. 2008. View Article : Google Scholar : PubMed/NCBI

36 

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI

37 

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI

38 

Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL and Jiang F: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 127:2870–2878. 2010. View Article : Google Scholar

39 

Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S and Tonini GP: Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. Mol Diagn. 8:93–100. 2004. View Article : Google Scholar : PubMed/NCBI

40 

Patnaik SK, Kannisto E, Knudsen S and Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70:36–45. 2010. View Article : Google Scholar

41 

Zhang G, Liu Z, Cui G, Wang X and Yang Z: MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol. 35:11137–11145. 2014. View Article : Google Scholar : PubMed/NCBI

42 

Pang W, Tian X, Bai F, Han R, Wang J, Shen H, Zhang X, Liu Y, Yan X, Jiang F, et al: Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer. 13:2402014. View Article : Google Scholar : PubMed/NCBI

43 

Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G and Yang Q: MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene. 33:3119–3128. 2014. View Article : Google Scholar

44 

Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. 130:2044–2053. 2012. View Article : Google Scholar

45 

Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A and Annilo T: Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 132:2884–2893. 2013. View Article : Google Scholar

Related Articles

Journal Cover

October-2015
Volume 34 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D, Liu Z and Huang J: Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer. Oncol Rep 34: 1779-1786, 2015
APA
Zhu, J., Zeng, Y., Xu, C., Qin, H., Lei, Z., Shen, D. ... Huang, J. (2015). Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer. Oncology Reports, 34, 1779-1786. https://doi.org/10.3892/or.2015.4141
MLA
Zhu, J., Zeng, Y., Xu, C., Qin, H., Lei, Z., Shen, D., Liu, Z., Huang, J."Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer". Oncology Reports 34.4 (2015): 1779-1786.
Chicago
Zhu, J., Zeng, Y., Xu, C., Qin, H., Lei, Z., Shen, D., Liu, Z., Huang, J."Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer". Oncology Reports 34, no. 4 (2015): 1779-1786. https://doi.org/10.3892/or.2015.4141